Sean E. Connolly

Sean E. Connolly

Auto-generated profile, based on publicly available information

Sean E. Connolly

Bristol‐Myers Squibb Princeton New Jersey

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JSJeremy Sokolove
Jeremy Sokolove
MSMichael Schiff
Michael Schiff
RFRoy Fleischmann
Roy Fleischmann
MWMichael E Weinblatt
Michael E Weinblatt
SCSean E Connolly
Sean E Connolly
WRWilliam H Robinson
William H Robinson
Objectives To examine whether baseline anti-cyclic citrullinated peptide-2 (CCP2) antibody status and concentration correlated with clinical outcomes in patients treated with abatacept or adalimumab on background methotrexate (MTX) in the 2-year AMPLE (Abatacept versus adaliMumab comParison in bioLogic-naïvE rheumatoid arthritis subjects with background MTX) study. Methods In this exploratory analysis, anti-CCP2 antibody concentration was measured at baseline, and antibody-positive patients were divided into equal quartiles, Q1–Q4, representing increasing antibody concentrations. Clinical outcomes analysed by baseline anti-CCP2 status and quartile included change from baseline in disease activity and disability and remission rates. Results Baseline characteristics were generally comparable across quartiles and treatment groups. In both treatment groups, anti-CCP2 antibody-negative patients responded less well than antibody-positive patients. At year 2, improvements in disease activity and disability and remission rates were similar across Q1–Q3, but were numerically higher in Q4 in the abatacept group; in contrast, treatment effects were similar across all quartiles in the adalimumab group. Conclusions In AMPLE, baseline anti-CCP2 positivity was associated with a better response for abatacept and adalimumab. Patients with the highest baseline anti-CCP2 antibody concentrations had better clinical response with abatacept than patients with lower concentrations, an association that was not observed with adalimumab. Trial registration number NCT00929864.

15 September 2001 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SCSean E Connolly
Sean E Connolly
JBJorge L. Benach
Jorge L. Benach
Abs are the major effectors of host defense against infections with Borrelia. Bactericidal murine mAbs and their Fabs destroy B. burgdorferi, the agent of Lyme disease, and relapsing fever Borrelia in the absence of complement. These in vitro observations led to the expansion of a search for functionally similar Abs in vivo. In this study, we demonstrate that functionally unique IgM Abs develop in vivo and are responsible for the elimination of spirochetemia in murine models of relapsing fever, without the assistance of complement. Mice deficient in the fifth or third component of complement can clear the spirochetemia, whereas B cell-deficient mice cannot. The B cell-deficient mice developed spirochetemia that was an order of magnitude higher and persisted for a longer period of time in comparison to the wild-type mice. Additionally, B cell-deficient mice passively immunized with immune IgM and with immune serum were protected from challenge.

18 June 2019 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MGMichael D. George
Michael D. George
JBJoshua F. Baker
Joshua F. Baker
KWKevin Winthrop
Kevin Winthrop
EAEvo Alemao
Evo Alemao
LCLang Chen
Lang Chen
JCJeffrey R. Curtis
Jeffrey R. Curtis
Patients, particularly those with rheumatoid arthritis (RA), are at increased risk for infection after major surgery. In this analysis, the authors examined risk for infection across different biol... Background: Patients with rheumatoid arthritis (RA) are at increased risk for infection after arthroplasty, yet risks of specific biologic medications are unknown. Objective: To compare risk for po...

1 May 2005 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
SCSean E. Connolly
Sean E. Connolly
JBJorge L. Benach
Jorge L. Benach

15 January 2004 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SCSean E Connolly
Sean E Connolly
DTDavid G. Thanassi
David G. Thanassi
JBJorge L. Benach
Jorge L. Benach
The spirochetemia of relapsing fever in mice is cleared by a complement-independent, polyclonal IgM response with reactivity to two prominent Ags of 20 and 35 kDa. In this study, we have dissected the polyclonal IgM Ab response against a relapsing fever spirochete to determine the specificity of its complement-independent bactericidal properties. Our experimental approach selectively generated an IgM murine mAb from the early specific immune response to a variable outer membrane protein. This IgM is bactericidal in the absence of complement and is part of the polyclonal Ab response that mediates the clearance of this bacterium from the blood. Purified monoclonal IgM caused direct structural damage to the outer membrane of the spirochete, in the absence of complement, and protected both B cell- and C5-deficient mice from challenge when administered passively. The direct, complement-independent, bactericidal activity of Abs is a critical mechanism of host defense against infection.

1 November 2017 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
LHLeslie R. Harrold
Leslie R. Harrold
HLHeather J. Litman
Heather J. Litman
SCSean E. Connolly
Sean E. Connolly
SKSheila Kelly
Sheila Kelly
WHWinnie Hua
Winnie Hua
JKJoel M. Kremer
Joel M. Kremer
Objective.: Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-α inhibitor (TNFi).Methods.: Using the Corrona RA registry, patients were identified who initiated ABA or a TNFi (June 2004–January 2015), had a followup visit 6 months (± 3 mos) after initiation, and anti-CCP measured at or prior to initiation. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) from initiation to 6 months. Treatment response was evaluated based on a typical patient profile (female, aged 57 yrs, body mass index of 30 kg/m2, baseline CDAI of 20, 1 prior biologic, and no comorbidities other than RA). Secondary outcomes included remission and low disease activity.Results.: There were 566 ABA initiators [anti-CCP+ (≥ 20 units/ml): n = 362; anti-CCP− (< 20 units/ml): n = 204] and 1715 TNFi initiators (anti-CCP+: n = 1113; anti-CCP−: n = 602). Differences between treatment groups included baseline disease duration, CDAI, and prior biologic use. At 6 months, anti-CCP+ ABA initiators were associated with significantly greater CDAI response versus anti-CCP− ABA initiators; no significant difference was observed for TNFi initiators. When considering a typical RA patient profile, CDAI response was greater in anti-CCP+ versus anti-CCP− ABA initiators; anti-CCP+ versus anti-CCP− TNFi initiators were similar. Secondary outcome responses were also greater in anti-CCP+ versus anti-CCP− ABA initiators; TNFi initiators did not differ by anti-CCP status.Conclusion.: In a US-based clinical practice setting, anti-CCP status was associated with a differential treatment response to ABA, but not TNFi.